COCP - Cocrystal Pharma to test CDI-45205 against coronaviruses

Cocrystal Pharma ([[COCP]] -9.2%) has selected CDI-45205 as the lead compound for further development against coronaviruses including SARS-CoV-2.CDI-45205 was one of the broad spectrum protease inhibitors that were obtained by an exclusive license from Kansas State University Research Foundation under an agreement announced in April this year.“We see significant potential for delivering this compound either by injection or inhalation and for potential use as both a therapeutic and prophylactic", said Sam Lee, President.Active Pharmaceutical ingredient synthesis and IND-enabling studies is up next.

For further details see:

Cocrystal Pharma to test CDI-45205 against coronaviruses